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Objectives The purpose of this study is to evaluate the efficacy and safety of ticagrelor and clopidogrel in patients with acute coronary
syndrome undergoing coronary artery bypass graft surgery (CABG), as a post-randomization strategy.
Background Ticagrelor is a novel, reversibly binding, oral, direct-acting P2Y12-receptor antagonist. In the PLATO (Platelet Inhibition and
Patient Outcomes) trial, which randomized 18,624 patients with acute coronary syndromes, ticagrelor compared with clopi-
dogrel significantly reduced the risk of the primary composite end point of cardiovascular (CV) death, myocardial infarction,
or stroke (hazard ratio [HR]: 0.84; 95% confidence interval [CI]: 0.77 to 0.92; p 0.001). This report investigated the out-
comes of patients treated with CABG during the trial.
Methods In total, 1,899 patients underwent CABG post-randomization. The protocol recommended ticagrelor/placebo to be
withheld for 24 to 72 h and clopidogrel/placebo for 5 days preoperatively. In all, 1,261 patients underwent CABG and
were receiving study drug treatment 7 days before surgery. The statistical analysis was based on events occurring
from the CABG procedure until the end of the study, excluding 3 patients with CABG after study end.
Results In the 1,261 patient cohort, the relative reduction of primary composite end point at 12 months (10.6% [66 of 629]
with ticagrelor versus 13.1% [79 of 629] with clopidogrel; HR: 0.84; 95% CI: 0.60 to 1.16; p  0.29) was consistent
with the results of the whole trial. Total mortality was reduced from 9.7% (58 of 629) to 4.7% (29 of 629; HR: 0.49;
95% CI: 0.32 to 0.77; p  0.01), CV death from 7.9% (47 of 629) to 4.1% (25 of 629; HR: 0.52; 95% CI: 0.32 to
0.85; p  0.01), and non-CV death numerically from 2.0% to 0.7% (p  0.07). There was no significant difference in
CABG-related major bleeding between the randomized treatments.
Conclusions In the subgroup of patients undergoing CABG within 7 days after the last study drug intake, ticagrelor compared with
clopidogrel was associated with a substantial reduction in total and CV mortality without excess risk of CABG-related
bleeding. (J Am Coll Cardiol 2011;57:672–84) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.029The currently recommended dual antiplatelet treatment of
patients with acute coronary syndrome (ACS) or stenting
reduces the risk of major adverse ischemic cardiovascular
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February 8, 2011:672–84 Results From the PLATO Trialthough recent international guidelines recommend the early
start of dual antiplatelet therapy with aspirin and a thien-
opyridine for patients with acute coronary syndromes, this
strategy is controversial because of the excess risk of bleed-
ing complications in patients undergoing urgent bypass
surgery (6,7). The currently used combination of aspirin and
thienopyridine (clopidogrel or prasugrel) provides irrevers-
ible platelet inhibition with recovery of platelet function
after 5 to 7 days by the production of new platelets.
Ticagrelor, the first reversibly binding, direct-acting oral
P2Y12 receptor antagonist leads to greater and more con-
sistent P2Y12 inhibition than clopidogrel, with more rapid
onset and offset of P2Y12 inhibition than clopidogrel
8 –12). For patients with a need of CABG surgery, the
nterval after cessation of P2Y12 inhibition might there-
See page 685
fore be shortened to 2 to 3 days with ticagrelor rather than
the 5 to 7 days recommended with clopidogrel and/or
prasugrel. The PLATO (Platelet Inhibition and Patient
Outcomes) trial found that ticagrelor was superior to clopi-
dogrel for the prevention of cardiovascular and total death,
myocardial infarction (MI), and stent thrombosis without an
increase in major bleeding in a population with ACS (13).
Among the 18,624 patients included in the main PLATO
trial, 10.2% (n 1,899) underwent CABG at any time during
the trial after randomization, and 6.8% (n  1,261) had
CABG within 7 days after discontinuation of study treatment.
The objective of this post-randomization analysis was to
investigate the efficacy and safety outcome in this subgroup of
PLATO study.
Methods
The PLATO trial (NCT00391872) was an international,
prospective, randomized, double-blind, double-dummy,
event-driven study of 18,624 patients hospitalized for either
acute ST-segment elevation ACS with an intention for
primary percutaneous coronary intervention (PCI) or non–
ST-segment elevation ACS, managed invasively or medi-
cally. Details of the study design, population, and outcomes
have been published previously (14). In brief, patients were
randomly assigned to treatment with either ticagrelor or
clopidogrel within 24 h of onset of the most recent cardiac
ischemic symptoms and before PCI. Ticagrelor-assigned
patients received a 180-mg loading dose followed by a
maintenance dose of 90 mg twice daily (bid). Clopidogrel-
treated patients not already receiving a loading dose of
open-label clopidogrel or who had not been taking clopi-
dogrel or ticlopidine for 5 days before randomization,
eceived a loading dose of 300 mg, followed by a mainte-
ance dose of 75 mg once daily. The remaining patients
eceived the 75-mg daily maintenance dose of clopidogrel as
heir first dose. Patients undergoing PCI received 1) an
dditional 90-mg dose of ticagrelor/placebo at procedures24 h after randomization, and
2) at the discretion of the inves-
tigator, an additional 300 mg
clopidogrel/placebo at any time
relative to randomization. All
patients received a dose of acetyl-
salicylic acid (ASA) 75 to 100
mg per day unless intolerant. For
patients not previously receiving
ASA, a loading dose of 325 mg
was preferred (although a dose of
160 to 500 mg was allowed).
After stent placement, an ASA
dose up to 325 mg daily was
allowed for as long as 6 months,
and the low dose used thereafter.
Randomized treatment contin-
ued for 6 to 12 months.
For patients undergoing coronary artery bypass graft
surgery (CABG), it was recommended that the study drugs
would be withheld before surgery, 5 days for clopidogrel
study drug and 24 to 72 h for ticagrelor study drug, while
maintaining study blind. It was also recommended that the
study drug be restarted as soon as possible after surgery and
before discharge.
Events. The detailed definitions of efficacy and safety
outcome events have been previously presented (14). Death
from vascular causes included cardiovascular death, cerebrovas-
cular death, and any death without noncardiovascular cause.
Myocardial infarction was defined in accordance with the
recently proposed universal definition (15). Periprocedural MI
within 24 h after CABG was defined as either: 1) creatine
kinase–myocardial band (CK-MB) 5 times local or central
laboratory upper limit of normal (ULN), and, if the pre-
CABG CK-MB was more than the ULN, both an increase by
at least 50% over the previous value and documentation that
CK-MB was decreasing before the suspected recurrent MI and
development of new pathological Q waves on the electrocar-
diogram (no symptoms are required); or 2) CK-MB 10
times local or central laboratory ULN and, if the pre-CABG
CK-MB was more than the ULN, both an increase by at least
50% over the previous value and documentation that CK-MB
was decreasing before the suspected recurrent MI (with or
without Q waves; no symptoms are required). Stroke was
defined as focal loss of neurological function caused by an
ischemic or hemorrhagic event with residual symptoms lasting
at least 24 h or leading to death.
The primary safety end point was PLATO study defined
total major bleeding (13,14). Major life-threatening bleed-
ing was defined as fatal bleeding, intracranial bleeding,
intrapericardial bleeding with cardiac tamponade, hypovo-
lemic shock or severe hypotension due to bleeding requiring
pressors or surgery, a fall in hemoglobin of 50 g/l (3.1
mmol/l) or greater, or need for transfusion of at least 4 units
of red blood cells. We defined other major bleeding as
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CABG  coronary artery
bypass graft surgery
CI  confidence interval
CK-MB  creatine kinase-
myocardial band
CV  cardiovascular
HR  hazard ratio
PCI  percutaneous
coronary intervention
ULN  upper limit of
normalsignificantly disabling (such as intraocular bleeding with
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Results From the PLATO Trial February 8, 2011:672–84permanent vision loss), a drop in hemoglobin of at least 30
g/l (1.9 mmol/l) but 50 g/l (3.1 mmol/l) or requiring
transfusion of 2 to 3 units of red blood cells. The TIMI
(Thrombolysis In Myocardial Infarction) criterion for major
bleeding was programmed from the electronic case record
form (eCRF), using a cut-point of50 g of hemoglobin per
liter, but did not necessarily require clinical evidence of
excessive bleeding post-CABG. The GUSTO (Global Use
of Strategies to Open Occluded Coronary Arteries) study
definition of severe bleeding was derived from eCRF spe-
cific questions and was defined as fatal, intracranial, intra-
pericardial bleed with cardiac tamponade, or development
of hypovolemic shock or severe hypotension due to bleeding
requiring pressor support or surgery; and each of these items
was specified by the investigators on the bleeding event
form. Minor bleeding was defined as any bleeding requiring
medical intervention but not meeting the criteria for major
bleeding.
An independent central adjudication committee adjudi-
cated all suspected primary and secondary efficacy end
points as well as major and minor bleeding events, and in
addition, all patients with CABG were adjudicated con-
cerning occurrence of any of these outcome events.
Statistics. The primary efficacy end point was time from
CABG to first occurrence of any event from the composite
of death from vascular causes, MI, or stroke. Other efficacy
end points were the individual components of the primary
end point, all-cause mortality, and CABG-related mortal-
ity. The primary safety end point was time from CABG to
the first occurrence of any major bleeding event. The efficacy
analyses comprised all patients who were randomized to
study treatment and underwent a CABG with last intake of
study drug within 7 days before surgery; events occurring
after end of trial, withdrawal of consent, or last contact with
the patient were censored. The safety analyses on bleeding
comprised all patients who were randomized to study
treatment and underwent CABG with intake of study drug
within 7 days before surgery, with censoring of events
occurring 7 days after permanently stopping study medi-
cation. Baseline characteristics and procedures in hospital or
at discharge were compared between treatment groups with
the use of either Fisher’s exact (categorical variables) or
Wilcoxon rank-sum test (continuous variables). A Cox
proportional hazards model, with a factor for treatment
group, was used to analyze time-to-event end points.
Fisher’s exact test was used to analyze binary end points.
The consistency of effects with regard to the timing of stop
of study drug before CABG was analyzed with an interac-
tion effect model based on either Cox proportional hazards
model (time-to-event outcomes) or a logistic regression
model (binary outcomes). A p value 0.05 was regarded as
statistically significant. No adjustment for multiplicity was
performed. All analyses were done with SAS software
(version 9.2, SAS Institute, Cary, North Carolina).Results
Overall, 18 624 patients with ACS from 862 centers in 43
countries between October 2006 and July 2008 were ran-
domized in the trial. Of these, 1,899 (10.2%) patients
underwent CABG during the trial, 1,849 (9.9%) received at
least 1 dose of study drug, and 1,584 (8.5%) had CABG
between first and last intake of study drug (study drug
stopped at any time before CABG, even remotely). A total
of 1,261 (6.8%) patients underwent CABG with last intake
of study drug within 7 days before surgery (Fig. 1), of which
632 patients received ticagrelor and 629 patients received
clopidogrel and constituted the patient population in this
study. Three ticagrelor patients were excluded as they had
missing values for the efficacy end points because the CABG
as performed after the censoring date at 12 months.
The 2 treatment groups were balanced with regard to
aseline characteristics, in-hospital treatments, and proce-
ures (Tables 1 and 2). Median age was 64 years, and 21%
ere women. Previous PCI and CABG was noted in 10.4%
nd 1.5%, respectively. Chronic renal disease occurred in
.8%. Almost all patients (94%) were receiving aspirin before
andomization. Open-label clopidogrel pre-randomization
Figure 1 Study Population Undergoing CABG
by Randomized Treatment Assignment
Study population undergoing coronary artery bypass graft surgery (CABG)
by randomized treatment assignment.
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February 8, 2011:672–84 Results From the PLATO Trial(any dose) had been used in 46.5% of ticagrelor-treated
patients and in 44.2% of clopidogrel-treated patients (Table 3).
Of patients receiving both open-label clopidogrel and clopi-
dogrel/placebo, 82% had received 300 mg and 18%, 600 mg,
respectively. The randomized treatment was given for a me-
dian duration of 224 days.
A majority of the CABG procedures (57%) were per-
formed during the initial hospitalization. As illustrated in
Figure 2, most procedures were undertaken within the first
60 days. When invasive treatment was planned at study
entry, CABG was performed earlier. However, across the
whole study period, at least as many patients in the group
with “planned noninvasive strategy” as with “planned inva-
sive strategy” ultimately underwent CABG. The time to
CABG after randomization did not differ between
ticagrelor- and clopidogrel-treated patients (hazard ratio
[HR]: 0.96; 95% confidence interval [CI]: 0.87 to 1.05; p
Baseline Characteristics in the Study PopulatioTable 1 Baseline Characteristics in the Stu
Characteristic Ticagrelor
Age, yrs 64 (56
Age 75 yrs 86 (13
Women 121 (19
Weight, kg 70 (64
Weight 60 kg 16 (13
Height, cm 162 (15
BMI, kg/m2 26.8 (24
Waist circumference, cm 98 (89
Men 511 (80
Weight, kg 82 (73
Weight 60 kg 15 (2.9
Height, cm 172 (16
BMI, kg/m2 27.6 (25
Waist circumference, cm 99 (91
Race
White 588 (93
Black 8 (1.3
Oriental 26 (4.1
Other 10 (1.6
CV risk factors
Smoker 208 (32
Hypertension 433 (68
Dyslipidemia 356 (56
Diabetes mellitus 193 (30
History
Angina pectoris 344 (54
Myocardial infarction 124 (19
Congestive heart failure 30 (4.7
Percutaneous coronary intervention 58 (9.2
Coronary artery bypass graft 5 (0.8
Transient ischemic attack 21 (3.3
Nonhemorrhagic stroke 24 (3.8
Peripheral arterial disease 43 (6.8
Chronic renal disease 33 (5.2
Values are median (25th–75th percentiles) or n (%). *The p values wer
sum test (continuous variables).
BMI  body mass index; CV  cardiovascular.0.36). Of all CABG procedures, 95% were without valvereplacement and 91% included the target vessel of index
event. The number of grafts were 0 in 3 (0.2%), 1 or 2 in
391 (31%), 3 or 4 in 754 (60%), and 5 in 100 (8%)
patients. In the ticagrelor group, investigational treatment
was discontinued within the first 2 days in 190 (30.1%)
patients, within 3 to 5 days in 277 (43.8%), and for 5 days
in 165 (26.1%), before surgery. Corresponding numbers for
patients in the clopidogrel group were 174 (27.7%), 338
(37.9%), and 217 (34.5%). Study drugs were restarted
within 7 days in 57% and in 84% within 14 days
post-CABG, with no difference between the treatment
groups.
Efficacy outcomes among patients undergoing CABG.
The occurrence of the primary end point (CV death, MI, or
stroke) with ticagrelor compared with clopidogrel from
CABG and onward was 10.6% versus 13.1% (HR: 0.84;
95% CI: 0.60 to 1.16; p  0.29) (Table 4) and was
andomizationpulation at Randomization
632) Clopidogrel (n  629) p Value*
64 (56–71) 0.3067
99 (15.7) 0.3013
145 (23.1) 0.0976
71 (63–80) 0.8035
23 (15.9) 0.6038
) 160 (156–165) 0.5386
.3) 27.1 (24.6–30.9) 0.9528
97 (90–107) 0.8978
484 (76.9) 0.0976
81 (72–90) 0.2584
16 (3.3) 0.8227
) 173 (168–178) 0.2792
.5) 26.9 (24.6–29.4) 0.0450
99 (91–107) 0.7374
588 (93.5) 0.9697
9 (1.4)
23 (3.7)
9 (1.4)
185 (29.4) 0.1837
422 (67.1) 0.6297
328 (52.1) 0.1419
207 (32.9) 0.3969
327 (52.0) 0.3975
131 (20.8) 0.6238
22 (3.5) 0.3216
73 (11.6) 0.1669
14 (2.2) 0.0395
18 (2.9) 0.7454
25 (4.0) 0.8853
53 (8.4) 0.2899
27 (4.3) 0.5087
ated with Fisher’s exact test (categorical variables) or Wilcoxon’s rankn at Rdy Po
(n 
–71)
.6)
.1)
–80)
.2)
8–165
.8–31
–109)
.9)
–92)
)
8–177
.0–30
–108)
.0)
)
)
)
.9)
.5)
.3)
.5)
.4)
.6)
)
)
)
)
)
)
)
e calculconsistent with the results in the whole trial. The rate of MI
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Results From the PLATO Trial February 8, 2011:672–84or stroke at or after CABG did not differ between the 2
treatment groups. The difference in the composite outcome
was driven by a reduction in CV death from 7.9% (47 of
629) for clopidogrel, to 4.1% (25 of 631) for ticagrelor (HR:
0.52; 95% CI: 0.32 to 0.85; p  0.01) (Table 4, Fig. 3B).
Total mortality in association with or after CABG was
reduced from 9.7% (58 of 629) to 4.7% (29 of 629; HR:
0.49; 95% CI: 0.32 to 0.77; p  0.01) (Table 4, Fig. 3A).
Also non-CV death was numerically reduced from 2.0% to
0.7% (HR: 0.35; 95% CI: 0.11 to 1.11; p  0.07). There
was no significant treatment by subgroup interaction for the
outcomes of: 1) the primary efficacy composite; and 2) total;
or 3) CV mortality for the following subgroups: open-label
clopidogrel before randomization, hypertension, diabetes
mellitus, smoking, dyslipidemia, or age 75 years or 75
ears, weight 60 or 60 kg or 80 or 80 kg, or waist
100 cm or 100 cm. For sex, p values for interaction were
0.01 for total mortality and0.05 for CV mortality, but not
ignificant for the primary composite. The hazard ratios for
otal mortality were 0.29 (95% CI: 0.16 to 0.55) and 1.16
95% CI: 0.59 to 2.31) for males and females, respectively.
CABG Evaluations, Treatments, and Proceduresin Hospit or at Disch rge for Index Event (n Table 2 CABG Evaluation , Tr atments, andin Hospital or at Discharge for Inde
Characteristic
Abnormal physical findings
Heart rate, beats/min
Systolic blood pressure, mm Hg
Diastolic blood pressure, mm Hg
Killip class 2
Persistent ST-segment elevation 1 mm/LBBB/final diagn
TIMI STEMI risk score 2†
Antithrombotic treatment in hospital
Aspirin before randomization
Aspirin after randomization
Unfractionated heparin
Low-molecular-weight heparin
Fondaparinux
Bivalirudin
Glycoprotein IIb/IIIa inhibitor
Other medication in hospital
Beta-blocker
ACE inhibitor and/or ARB
Cholesterol lowering (statin)
Calcium-channel inhibitor
Diuretics
Proton-pump inhibitor
Invasive procedures in hospital
Coronary angiography
PCI within 24 h of randomization
Any PCI pre-discharge
Any CABG pre-discharge
Values are median (25th–75th percentiles) or n (%). *The p values wer
sum test (continuous variables). †The TIMI (Thrombolysis In Myocard
score 2 in percentage of patients with persistent ST-segment elevat
ACE  angiotensin-converting enzyme; ARB  angiotensin-receptor
coronary intervention.he hazard ratios for CV mortality were 0.32 (95% CI: 0.16 1o 0.63) and 1.15 (95% CI: 0.56 to 2.39) for males and
emales, respectively.
A sensitivity analysis of the total CABG population (n 
,899), showed consistent results with the study population.
he reduction in total mortality in association with or after
ABG, was reduced from 8.4% to 5.0% (HR: 0.60; 95% CI:
.42 to 0.87; p  0.01), and CV death was decreased from
.8% to 4.1% (HR: 0.61; 95% CI: 0.41 to 0.92; p  0.05).
ost-CABG mortality in relation to time from last study
rug before surgery. In a further exploratory hypothesis-
enerating analysis, total and CV mortality post-CABG
ere analyzed in relation to days from last intake of study
rugs before CABG surgery, as shown in Figure 4. The p
alue for interaction was of borderline significance (p 
.06) for total mortality overall. There was no mortality
ifference between ticagrelor and clopidogrel when last
ntake was 1 day or less. However, if last intake of study
rug was 2, 3, or 4 days before surgery, there were
ignificant reductions in total mortality. When grouping
nto time intervals of last intake of study drugs, stopping 1
o 4 days before CABG, total mortality was 3.4% versus
1)edures
nt (n  1,261)
Ticagrelor
(n  632)
Clopidogrel
(n  629) p Value*
108 (17.1) 107 (17.0) 0.1896
72 (64–82) 73 (65–84) 0.2016
131 (120–150) 132 (120–150) 0.6035
80 (70–89) 80 (70–87) 0.3708
9 (1.4) 11 (1.8) 0.6604
EMI 206 (32.6) 210 (33.4) 0.8107
122 (59.2) 116 (55.2) 0.4291
597 (94.5) 587 (93.3) 0.4127
614 (97.2) 611 (97.1) 1.0000
356 (56.3) 355 (56.4) 1.0000
393 (62.2) 381 (60.6) 0.5635
20 (3.2) 18 (2.9) 0.8694
2 (0.3) 5 (0.8) 0.2867
134 (21.2) 141 (22.4) 0.6332
578 (91.5) 563 (89.5) 0.2505
521 (82.4) 532 (84.6) 0.3243
612 (96.8) 613 (97.5) 0.6126
181 (28.6) 189 (30.0) 0.6208
370 (58.5) 369 (58.7) 1.0000
345 (54.6) 376 (59.8) 0.0686
564 (89.2) 567 (90.1) 0.6436
112 (17.7) 126 (20.0) 0.3139
130 (20.6) 135 (21.5) 0.7298
352 (55.7) 368 (58.5) 0.3335
ated with Fisher’s exact test (categorical variables) or Wilcoxon’s rank
ction) study ST-segment elevation myocardial infarction (STEMI) risk
mm or left bundle branch block (LBBB) or final diagnosis STEMI.
r; CABG  coronary artery bypass graft surgery; PCI  percutaneous1,26Proc
x Eve
osis ST
e calcul
ial Infar
ion 15.5% (HR: 0.21; 95% CI: 0.10 to 0.42; p  0.01 for
roduct
677JACC Vol. 57, No. 6, 2011 Held et al.
February 8, 2011:672–84 Results From the PLATO Trialinteraction), and corresponding CV mortality was 3.1%
versus 11.8% (HR: 0.25; 95% CI: 0.12 to 0.53; p  0.05 for
interaction), in the ticagrelor-treated patients compared
Detailed Information on the Randomized TreatmTable 3 Detailed Information on the Random
Characteristic Ticagrelor (n
Treatment duration, days 226 (24–3
Delay from start of pain, h 14.4 (6.9–
Delay from hospital admission, h 9.0 (2.3–
OLIP/placebo
300 mg 527 (83.4
600 mg 105 (16.6
OL clopidogrel pre-randomization
None 338 (53.5
75 mg (50–150 mg) 94 (14.9
300 mg (151–449 mg) 142 (22.5
600 mg (450 mg) 58 (9.2)
Study drug stopped before CABG
1 day before CABG 84 (13.3
2 days before CABG 106 (16.8
3 days before CABG 114 (18.0
4 days before CABG 84 (13.3
5 days before CABG 79 (12.5
6 days before CABG 91 (14.4
7 days before CABG 74 (11.7
Restarted drug after CABG
Did not restart 234 (37.0
7 days 227 (35.9
7–14 days 111 (17.6
14 days 60 (9.5)
Values are median (25th–75th percentiles) or n (%). *The p values wer
sum test (continuous variables).
CABG  coronary artery bypass graft surgery; IP  investigational p
Figure 2 Timing of CABG From Randomization
Kaplan-Meier curve illustrating time from randomization to coronary artery bypass
and clopidogrel (dashed line) in the total study population.with clopidogrel-treated patients. When last study drug
intake was 4 days before CABG, there was no difference
in mortality between the study drugs.
Treatment
) Clopidogrel (n  629) p Value*
223 (28–363) 0.9186
13.5 (6.7–20.8) 0.6007
6.8 (2.2–15.7) 0.0932
0.3376
511 (81.2)
118 (18.8)
0.0462
351 (55.8)
66 (10.5)
135 (21.5)
77 (12.2)
0.0012
88 (14.0)
86 (13.7)
73 (11.6)
69 (11.0)
96 (15.3)
110 (17.5)
107 (17.0)
0.8267
238 (37.8)
225 (35.8)
100 (15.9)
66 (10.5)
ated with Fisher’s exact test (categorical variables) or Wilcoxon’s rank
(blinded); OL  open label.
urgery (CABG) by ticagrelor (solid line)entized
 632
64)
20.4)
17.0)
)
)
)
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)
)
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Results From the PLATO Trial February 8, 2011:672–84Bleeding among patients undergoing CABG. Nearly all
bleeding events occurred within 24 h post-CABG. Overall,
according to the PLATO study definitions, major CABG-
related bleeding occurred in 81.3% versus 80.1% (HR: 1.01;
95% CI: 0.90 to 1.15; p  0.84) of the ticagrelor- and
clopidogrel-assigned patients, respectively (Table 5). Cor-
respondingly, life-threatening/fatal CABG-related bleeds
occurred in 42.6% versus 43.7% (HR: 1.02; 95% CI: 0.87 to
1.21; p  0.77). Bleeding according to TIMI major criteria
ccurred in 57.6% versus 59.3% (HR: 1.03; 95% CI: 0.89 to
.19; p  0.68) and TIMI minor criteria in 21.6% versus
1.1% (HR: 0.97; 95% CI: 0.77 to 1.24; p  0.82), in the
espective clopidogrel and ticagrelor groups. Similarly, the
USTO study severe bleeding rates were 10.6% versus
2.2% (HR: 0.87; 95% CI: 0.62 to 1.20; p  0.39). Fatal
leeds were uncommon: 5 in the ticagrelor group and 6 in
he clopidogrel group. There were 2 intracranial bleeds, 1 in
ach treatment group.
There was no difference in CABG-related hemoglobin
rop 50 g/l occurring in 228 (36%) in the respective
lopidogrel group versus 241 (38%) in the ticagrelor group,
or in any transfusion within 7 days of the CABG that was
iven in 351 (56%) patients versus 349 (55%) patients,
espectively. Neither was there any difference in CABG-
elated bleeds leading to transfusion of 4 U of blood as
oted in, respectively, 102 (16.2%) patients versus 113
17.9%) patients. Furthermore, there was no difference in
ransfusion of platelets or fresh frozen plasma observed.
eoperation due to bleeding was infrequent and occurred in
1 (3.3%) patients assigned to clopidogrel and in 25 (4.0%)
atients receiving ticagrelor. Chest tube drainage of 2 l
as also rare but did not differ between the treatment
roups (Table 5). None of the various bleeding definition
ates differed between the ticagrelor group and the clopi-
ogrel group regardless of intake of open-label clopidogrel
re-randomization (p  0.80 for interaction).
Sensitivity analyses of the safety population (n  1,584)
ound consistent results, with no difference in bleeding rate
etween ticagrelor and clopidogrel for any of the life-
Outcome After Coronary Artery Bypass Graft SuTable 4 Outcome After Coronary Artery Byp
End Point
Ticagrelor*
(n  629)
Primary objective CV death/MI/stroke 66 (10.6)
MI, excluding silent 37 (6.0)
All-cause mortality 29 (4.7)
CV death 25 (4.1)
Non-CV death 4 (0.7)
Stroke 13 (2.1)
Hemorrhagic stroke 0 (0.0)
Nonhemorrhagic/unknown stroke 13 (2.1)
Values are number of events (%). *The percentage is the Kaplan-Meier
were calculated by means of Cox regression analysis.
CI  confidence interval; CV  cardiovascular; HR  hazard ratio; Mhreatening/major or minor bleeding definitions. tost-CABG bleeding in relation to time from last study
rug before surgery. There was no difference in PLATO
tudy major/fatal/life-threatening CABG-related bleeding
r GUSTO study severe bleeds between ticagrelor and
lopidogrel, with respect to time from last intake of study
rug before surgery, not even when the drug was stopped 1
ay before surgery (Table 6) (p  0.76 for interaction).
hest tube drainage measured over 24 h did not differ
etween treatment groups for any of 7 intervals between
essation of study drug and CABG (Fig. 5), either by total
illiliters of drainage or by percentage of patients with at
east 500 ml of drainage. Treatment groups also did not
iffer in the decrease in hemoglobin concentration adjusted
or red cell transfusion for any of the 7 intervals (Fig. 6).
igure 6 indicates less impact of perioperative bleeding on
emoglobin concentration when the interval is at least 5
ays.
iscussion
he current analysis showed that among patients initially
reated for ACS and subsequently undergoing CABG with
ast intake of study drug within 7 days before surgery,
icagrelor compared with clopidogrel was associated with
round a halving in total and CV mortality without any
hange in the risk of CABG-related bleeding. The absolute
eduction in total mortality was 5.0% per year, and for CV
ortality, 3.8% per year.
In the total PLATO trial, there was a significant 22%
elative and 1.4% per year absolute reduction in total
ortality. Thus, the lower mortality for patients treated
ith CABG is consistent with the overall trial results,
lthough more pronounced. The current analysis also indi-
ated a relationship between CABG mortality and the time
f last intake of study drug before surgery. Thus, there
ight be a special hazard associated with a remaining effect
f clopidogrel in association with surgery. The reasons for
he higher mortality in the clopidogrel group were, however,
ot related to bleeding complications. This lack of relationship
ight be in accordance with a recent registry study in which
in the Study Populationraft Surgery in the Study Population
Clopidogrel*
(n  629) HR (95% CI) p Value†
79 (13.1) 0.84 (0.60–1.16) 0.2862
35 (5.7) 1.06 (0.66–1.68) 0.8193
58 (9.7) 0.49 (0.32–0.77) 0.0018
47 (7.9) 0.52 (0.32–0.85) 0.0092
11 (2.0) 0.35 (0.11–1.11) 0.0748
11 (2.1) 1.17 (0.53–2.62) 0.6967
1 (0.2)
10 (1.9) 1.29 (0.57–2.95) 0.5430
te of the rate of the end point at 12 months post-CABG. †The p values
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February 8, 2011:672–84 Results From the PLATO Trialtions when clopidogrel treatment was stopped 5 days before
CABG (16). Also, the findings from the CABG subgroup in
the ACUITY (Acute Catheterization and Urgent Intervention
Triage Strategy) trial are consistent, with lack of increase in
bleeding regardless of upstream clopidogrel, although the
transfusion rate was higher among patients whose clopidogrel
was stopped 5 days before CABG (17). In our study, the
ime of stopping ticagrelor and clopidogrel before surgery
ffected the mortality rate, and especially in the time window
etween 1 and 4 days. The excess of fatalities in the current
tudy may have been caused by other cardiovascular events, for
xample, arrhythmia/sudden death and heart failure, and also
y noncardiovascular events, such as infections or sepsis. The
Figure 3 Cumulative Risk of Any Death or CV Death
Kaplan-Meier (K-M) curve showing (A) time from coronary artery bypass graft surge
the duration of randomized study treatment before CABG. Solid line  ticagrelor; dore frequent occurrence of sepsis at surgery in clopidogrel- hreated patients has previously been reported (18) as a potential
azard that might be contributing to worsening in outcomes
lso at CABG.
CABG differs from other major surgery in that it
ncludes full heparinization therapy, platelet dysfunction
rom the pump, and fibrinolysis, factors that all impact
he risk of bleeding (19). It is therefore not possible to
xtrapolate bleeding risk to other forms of major surgery.
espite the more intense platelet inhibition by ticagrelor
nd the shorter treatment-free interval before CABG,
here was no significant difference in the rate of major/
ife-threatening bleeding/fatal bleeding at surgery, or in
hest tube drainage, reoperation due to bleeding, or
BG) to any death or (B) or time to cardiovascular (CV) death, independent of
line  clopidogrel. CI  confidence interval; HR  hazard ratio.ry (CA
ashedemoglobin concentrations adjusted for red cell transfu-
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Results From the PLATO Trial February 8, 2011:672–84Figure 4 Cumulative Risk of Any Death by Last Intake of Study Drug
Total mortality among ticagrelor-treated patients (solid bars) and clopidogrel-treated patients (open bars) by days from last intake of study drug
before coronary artery bypass graft surgery.Bleeding Complications During and After CABGTable 5 Bleeding Complications During and After CABG
End Point
Ticagrelor*
(n  632)
Clopidogrel*
(n  629) OR/HR (95% CI) p Value†
Major CABG bleeds‡ 513 (81.2) 504 (80.1) 1.07 (0.80–1.43) 0.6691
CABG-related life-threatening/fatal‡ 276 (43.7) 268 (42.6) 1.04 (0.83–1.31) 0.7330
Fatal CABG bleeds‡ 5 (0.8) 6 (1.0) 0.83 (0.20–3.28) 0.7730
CABG-related intracranial bleeding‡ 0 (0.0) 0 (0.0)
All intracranial bleedings after CABG 1 (0.2) 1 (0.2) 1.01 (0.06–16.09) 0.9967
CABG TIMI, all major‡ 375 (59.3) 362 (57.6) 1.08 (0.85–1.36) 0.5300
CABG TIMI, minor‡ 133 (21.0) 136 (21.6) 0.97 (0.73–1.28) 0.8367
CABG-related GUSTO severe bleed‡ 67 (10.6) 77 (12.2) 0.85 (0.59–1.22) 0.3768
Any transfusion within 7 days after CABG 349 (55.7) 351 (56.5) 0.98 (0.85–1.14) 0.8336
PRBC or whole blood within 7 days after CABG 333 (53.2) 322 (51.9) 1.03 (0.88–1.20) 0.6948
Total blood transfusion within 7 days after CABG, no. of units§ 4.0 (2.0–9.0) 4.0 (2.0–8.0) 0.7616
PRBC or whole blood within 7 days after CABG, no. of units§ 3.0 (2.0–4.0) 3.0 (2.0–4.0) 0.8598
Platelets within 7 days after CABG 97 (15.4) 109 (17.5) 0.88 (0.67–1.16) 0.3705
Fresh frozen plasma within 7 days after CABG 159 (25.3) 151 (24.1) 1.05 (0.84–1.31) 0.6749
CABG-related bleed resulting in Hb decrease 50 g/l‡ 241 (38.1) 228 (36.2) 1.08 (0.86–1.37) 0.5216
CABG-related bleed resulting in Hb decrease 30 g/l‡ 442 (69.9) 425 (67.6) 1.12 (0.87–1.43) 0.3950
Major/life-threatening CABG-related bleeding resulting in death within 7 days after CABG 8 (1.3) 18 (3.0) 0.44 (0.19–1.01) 0.0524
Reoperation due to bleeding‡ 25 (4.0) 21 (3.3) 1.19 (0.63–2.27) 0.6528
CABG-related bleed resulting in transfusion 4‡ 113 (17.9) 102 (16.2) 1.12 (0.83–1.53) 0.4544
Transfusion whole blood/PRBC 5 U within 2 days after CABG‡ 31 (4.9) 25 (4.0) 1.25 (0.70–2.23) 0.4947
Chest tube output 2 l within 24 h‡ 21 (3.3) 17 (2.7) 1.24 (0.61–2.52) 0.6218
Chest tube output, ml, within 24 h§ 575 (300–950) 540 (320–810) 0.2447
Values are number of events (%). *For time-to-event outcomes, percent (%) is the Kaplan-Meier estimate of the rate of the end point at 12 months post-CABG. †The p values are from Cox regression analysis
(time-to-event outcomes) or Fisher’s exact test (binary outcomes). ‡Binary outcome with odds ratio (OR). §Median (25th–75th percentiles) and p value from Wilcoxon rank-sum test.
GUSTO  Global Use of Strategies to Open Occluded Coronary Arteries study; Hb  hemoglobin; PRBC  packed red blood cells; other abbreviations as in Tables 2 and 4.
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February 8, 2011:672–84 Results From the PLATO Trialsions. Bleeding around CABG is frequent, and a decrease
in hemoglobin 30 g/l or blood transfusions commonly
occur. Because of the rigorous application of the bleeding
definitions in the PLATO study, the criteria for major
bleeding were fulfilled in 80% of the CABG-treated
Figure 5 Chest Tube Drainage by Days From Last Intake of Stu
Chest tube drainage during 24 h, in milliliters (mean  SD, vertical axis), accordin
artery bypass graft surgery for ticagrelor (solid bars) and clopidogrel (open bars).
levels for the comparison between treatment groups by Student’s t test. Below th
ticagrelor/clopidogrel.
Bleeding Outcomes in Subgroups With Different Intervals BetweenCessation of Study Treatment and CABG (n  1,261)Table 6 Blee ing Outcomes in Subgroups With Different IntervCessation of Study Treatment and CABG (n  1,261)
End Point Characteristic*
CABG-related life-threatening/fatal bleed Study drug stop before CABG
1 day
1–2 days
2–3 days
3–4 days
4–5 days
5–6 days
6 days
CABG-related GUSTO severe bleed Study drug stop before CABG
1 day
1–2 days
2–3 days
3–4 days
4–5 days
5–6 days
6 days
Values are number of events (%). *Percent (%) is the rate of the end point: (number of events div
days is 24 h to 48 h, and so forth. ‡Odds ratio and p value from logistic regression.
Abbreviations as in Tables 2, 4, and 5.patients. However, despite thorough analyses of the
occurrence of bleeding by a vast number of bleeding
definitions, there appeared no significant difference in
rate of CABG-associated bleeding between clopidogrel
and ticagrelor. Also, the reoperation rates were similar.
rug
e interval in days (horizontal axis) from cessation of study drug to coronary
denotes the number of patients, and the p value indicates nominal significance
ontal axis appear the percentages of patients with 500 ml for
etween
n
Ticagrelor†
(n  632)
Clopidogrel†
(n  629) OR (95% CI)‡
p Value
Interaction‡
0.7613
55 (65.5) 52 (59.1) 1.31 (0.71–2.44)
50 (47.2) 42 (48.8) 0.94 (0.53–1.65)
56 (49.1) 33 (45.2) 1.17 (0.65–2.11)
39 (46.4) 29 (42.0) 1.20 (0.63–2.27)
22 (27.8) 27 (28.1) 0.99 (0.51–1.91)
29 (31.9) 45 (40.9) 0.68 (0.38–1.21)
25 (33.8) 40 (37.4) 0.85 (0.46–1.59)
0.4400
12 (14.3) 17 (19.3) 0.70 (0.31–1.56)
11 (10.4) 16 (18.6) 0.51 (0.22–1.16)
16 (14.0) 10 (13.7) 1.03 (0.44–2.41)
10 (11.9) 8 (11.6) 1.03 (0.38–2.77)
7 (8.9) 5 (5.2) 1.77 (0.54–5.81)
4 (4.4) 12 (10.9) 0.38 (0.12–1.21)
7 (9.5) 9 (8.4) 1.14 (0.40–3.20)
n of group per level of characteristic) times 100%. †Characteristic: 1 day is 0 to 24 h, 1 to 2dy D
g to th
The N
e horizals B
Total,
172
192
187
153
175
201
181
172
192
187
153
175
201
181
ided by
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Results From the PLATO Trial February 8, 2011:672–84The lack of difference in bleeding, when using the more
potent direct and reversible P2Y12 inhibitor ticagrelor as
compared with clopidogrel, still might indicate a rela-
tively lower risk of bleeding in relation to platelet activity
at CABG. This is in contrast to the comparison of
prasugrel, the indirect and potent P2Y12 inhibitor, with
clopidogrel in the TRITON (Trial to Assess Improve-
ment in Therapeutic Outcomes by Optimizing Platelet
Inhibition With Prasugrel) study (20), inducing a four-
fold higher rate of major bleeding among patients under-
going CABG. However, also in the TRITON trial, there
were more fatalities after CABG in patients assigned to
clopidogrel than to prasugrel.
The PLATO trial allowed patients already on treatment
with clopidogrel to be randomized into the trial, leading to
that almost one-half of patients in both groups were
pre-treated with clopidogrel at entry in the trial. However,
open-label clopidogrel did not affect the efficacy or safety
results, since no significant interaction was observed. The
halving in mortality by using ticagrelor instead of clopi-
dogrel in association with CABG was striking and also
explained about a quarter of the mortality reduction in the
whole trial. The finding that the excess mortality with clopi-
dogrel was unrelated to differences in the rates of bleeding
raises the suspicion that clopidogrel treatment might be asso-
ciated with other specific risks in association with major
surgery. These observations might have relations to the lack of
any significant mortality benefits despite striking reductions in
the rate of myocardial infarction in the major studies compar-
ing clopidogrel with placebo in ACS (20–22).
Study limitations. The current study is a retrospective
analysis of a nonrandomized subgroup of a large prospective
randomized trial, and therefore provides exploratory infor-
Figure 6 Proportion of Patients With Decrease in Hemoglobin >
Percentage of patients (vertical axis) with net decrease in hemoglobin concentratio
(horizontal axis) from cessation of study drug to coronary artery bypass graft surge
significance levels for the comparison between treatment groups by the Fisher examation concerning the findings. The formal adjudication ofcauses of deaths in the main study distinguished between
death from vascular and nonvascular causes, but a further
subcategorization was not performed.
Conclusions
In ACS patients needing CABG during dual antiplatelet
treatment, ticagrelor as compared with clopidogrel reduces
CV and total death without an increase in major bleeding.
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